# Adlai Nortye

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adlai-nortye

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.adlainortye.com/
- Total disclosed funding: $250M
- Latest round: Series D (Jul 13, 2021)
- Investors on record: 15

## About

Based in Hangzhou, China, and founded in 2004, Adlai Nortye Ltd., trading as Adlai Nortye, was founded by Yang Lu. The company is a biopharmaceutical company focused on developing drugs for the treatment of cancer and metabolic diseases. In May 2026, Soleus Capital, Perceptive Advisors, ADAR1 Capital Management, MPM BioImpact, Octagon Capital, Eventide Asset Management, DAFNA Capital Management, Cormorant Asset Management, Columbia Threadneedle Investments, Balyasny Asset Management, Casdin Capital, Squadron Capital Management, and other investors acquired 11.32 million shares in Adlai Nortye for USD 150 million, or at USD 13.25 apiece, in a PIPE transaction.

The company specializes in biological medicine research and development, and it offers therapeutic treatments that help patients efficiently fight cancer and metabolic disorders. Adlai Nortye has 23 issued patents and 7 PCT publications. They have considerable experience in peptide and protein medicine and have expanded their knowledge to small compounds and therapeutic antibodies. In the pipeline, the company has multiple preclinical and clinical-stage drug candidates.

The company's revenue is generated by selling innovative drugs in the fields of tumor immunology and metabolic diseases, as well as providing related technical services.

## Funding rounds

- Series D, Jul 13, 2021, $100M — Wuxi Guolian Industrial Investment Private Equity Fund Management, Legend Star, TianGe, CS Capital, Triwise Capital, Tigermed, WuXi Biologics (Cayman) Inc.
- Series C, Aug 4, 2020, $100M — Hangzhou Tigermed Consulting Company Limited, Yingke Private Equity, ICBC Asset Management (Global), ATCG Holdings Ltd.
- Series B, Jun 26, 2018, $50M — Detong Capital, MPC, YuanMing Capital, Yahui Precision Medicine Fund

## Investors

- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series B
- MPC — Series B
- YuanMing Capital (https://capitalatlas.ai/funds/yuanming-capital) — Series B
- Yahui Precision Medicine Fund — Series B
- Hangzhou Tigermed Consulting Company Limited — Series C
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series C
- ICBC Asset Management (Global) — Series C
- ATCG Holdings Ltd. — Series C
- Wuxi Guolian Industrial Investment Private Equity Fund Management — Series D
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series D
- TianGe — Series D
- CS Capital — Series D
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series D
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series D
- WuXi Biologics (Cayman) Inc. — Series D